2-DOSE HEPLISAV-B MAKES SERIES COMPLETION MORE EFFICIENT1,2

Series completion is essential for protection3

A complete series of HEPLISAV-B is just 2 doses in 1 month1

HEPLISAV-B is a 2-dose, 1-month hepatitis B vaccine and Engerix-B is a 3-dose, 6-month hepatitis B vaccine[1,2] HEPLISAV-B is a 2-dose, 1-month hepatitis B vaccine and Engerix-B is a 3-dose, 6-month hepatitis B vaccine[1,2]

In a real-world study, a large healthcare system evaluated the impact of simply switching to HEPLISAV-B and found that…

2X more adults completed the HEPLISAV-B vaccine series than those starting with Engerix-B[4] 2X more adults completed the HEPLISAV-B vaccine series than those starting with Engerix-B[4]

In the era of universal adult hepatitis B vaccination…5

2-dose HEPLISAV-B may increase efficiency with less staff time, fewer wasted doses, and is easier for patients [1,2,4,6] 2-dose HEPLISAV-B may increase efficiency with less staff time, fewer wasted doses, and is easier for patients [1,2,4,6]

The Advisory Committee on Immunization Practices recommends the use of HEPLISAV-B for protecting adults at risk of hepatitis B infection7

Efficiency with prefilled syringes1

HEPLISAV-B comes in a package of 5 single-dose prefilled syringes[1] HEPLISAV-B comes in a package of 5 single-dose prefilled syringes[1]
  • Latex-free HEPLISAV-B prefilled syringes offer convenience
  • Compact packaging
  • Store in a refrigerator
  • Do not freeze

CDC-recommended vaccines are eligible for first-dollar coverage8,*

The Advisory Committee on Immunization Practices recommends vaccines for CDC review and publication; all recommendations are eligible for first-dollar coverage.8

Clinical studies have shown faster protection with HEPLISAV-B1,9

DISCOVER DATA
 

Important Safety Information

INDICATION

HEPLISAV-B is indicated for prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older.

IMPORTANT SAFETY INFORMATION

Do not administer HEPLISAV-B to individuals with a history of severe allergic reaction (e.g., anaphylaxis) after a previous dose of any hepatitis B vaccine or to any component of HEPLISAV-B, including yeast.

Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of HEPLISAV-B.

Immunocompromised persons, including individuals receiving immunosuppressant therapy, may have a diminished immune response to HEPLISAV-B.

Hepatitis B has a long incubation period. HEPLISAV-B may not prevent hepatitis B infection in individuals who have an unrecognized hepatitis B infection at the time of vaccine administration.

The most common patient-reported adverse reactions reported within 7 days of vaccination were injection site pain (23%-39%), fatigue (11%-17%), and headache (8%-17%).

References: 1. HEPLISAV-B [package insert]. Emeryville, CA: Dynavax Technologies Corporation; 2020. 2. Engerix-B [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2018. 3. Mast EE, Weinbaum CM, Fiore AE, et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: immunization of adults. MMWR Recomm Rep. 2006;55(RR-16):1-33. 4. Bruxvoort K, Slezak J, Huang R, et al. Association of number of doses with hepatitis B vaccine series completion in US adults. JAMA Netw Open. 2020;3(11):e2027577. doi:10.1001/jamanetworkopen.2020.27577 5. Centers for Disease Control and Prevention. Recommended adult immunization schedule for ages 19 years or older, United States, 2022. Accessed April 14, 2022. https://www.cdc.gov/vaccines/schedules/downloads/adult/adult-combined-schedule.pdf 6. Nelson JC, Bittner RC, Bounds L, et al. Compliance with multiple-dose vaccine schedules among older children, adolescents, and adults: results from a vaccine safety datalink study. Am J Public Health. 2009;99(suppl 2):S389-S397. doi:10.2105/AJPH.2008.151332 7. Kim DK, Hunter P; for the Advisory Committee on Immunization Practices. Recommended adult immunization schedule, United States, 2019. Ann Intern Med. 2019;170(3):182-192. doi:10.7326/M18-3600 8. Hughes R IV, Maxim R, Fix A. Vague vaccine recommendations may be leading to lack of provider clarity, confusion over coverage. Health Affairs Blog. May 7, 2019. Accessed April 14, 2022. https://www.healthaffairs.org/do/10.1377/forefront.20190506.172246 9. Dynavax Technologies Corporation. FDA Advisory Committee Briefing Document: HEPLISAV-B™ (Hepatitis B Vaccine [Recombinant], Adjuvanted). Presented at: Meeting of the Vaccines and Related Biological Products Advisory Committee; July 28, 2017; Silver Spring, MD.

See the CDC recommendation

INDICATION

HEPLISAV-B is indicated for prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older.

IMPORTANT SAFETY INFORMATION

Do not administer HEPLISAV-B to individuals with a history of severe allergic reaction (e.g., anaphylaxis) after a previous dose of any hepatitis B vaccine or to any component of HEPLISAV-B, including yeast.